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Abstract
 
The current view holds that chronic autoimmune diseases are driven by the continuous activation
of autoreactive B and T lymphocytes. However, despite the use of potent immunosuppressive
drugs designed to interfere with this activation the production of autoantibodies often persists
and contributes to progression of the immunopathology. In the present study, we analyzed the
life span of (auto)antibody-secreting cells in the spleens of NZB 
 
 
 
 NZW F1 (NZB/W) mice,
a murine model of systemic lupus erythematosus. The number of splenic ASCs increased in
mice aged 1–5 mo and became stable thereafter. Less than 60% of the splenic (auto)antibody-
secreting cells were short-lived plasmablasts, whereas 40% were nondividing, long-lived plasma
cells with a half-life of 
 
 
 
6 mo. In NZB/W mice and D42 Ig heavy chain knock-in mice, a
fraction of DNA-specific plasma cells were also long-lived. Although antiproliferative immuno-
suppressive therapy depleted short-lived plasmablasts, long-lived plasma cells survived and con-
tinued to produce (auto)antibodies. Thus, long-lived, autoreactive plasma cells are a relevant
target for researchers aiming to develop curative therapies for autoimmune diseases.
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Introduction
 
Autoimmune diseases are characterized by the activation of
autoantigen-specific T and B lymphocytes and by their
differentiation into autoreactive effector cells. Antibodies
secreted by autoreactive plasmablasts and plasma cells can
contribute significantly to autoimmune pathogenesis (1, 2).
Antibodies binding to double-stranded DNA characterize
human and murine systemic lupus erythematosus (SLE),
and their titers are an excellent measure of disease activity.
Some subgroups of these autoantibodies cause severe mani-
festations such as lupus nephritis and vascular injury. (3). It
is assumed that chronic autoantibody production is driven
by the continuous activation of autoreactive T and B lym-
phocytes (4–6). The latter cells differentiate into proliferating,
autoantibody-secreting plasmablasts, which in turn differenti-
ate into nonproliferating, short-lived plasma cells. However,
suppression of T and B lymphocyte activation with immuno-
suppressants often does not eliminate the production of
autoantibodies (7, 8). This could be due to the presence of
resistant autoreactive T and B lymphocytes with strength-
ened survival capabilities and a lowered threshold for activa-
tion (9, 10). Alternatively, long-lived, autoreactive plasma
cells might continue to secrete autoantibodies in the absence
of chronic activation of autoreactive T and B lymphocytes.
It was shown recently that plasma cells can survive in
the BM for extended periods of time, presumably from
several months to years (11). These long-lived plasma cells
do not divide and are resistant to irradiation and mitomycin
C (11–13). They no longer react to antigen or antigen-
antibody complexes (14). Their survival in the BM might
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be dependent on a complex molecular microenvironment
called the “plasma cell survival niche.” IL-5, IL-6, TNF-
 
 
 
,
SDF-1, and CD44-mediated signaling have been identified
as survival factors for plasma cells (15–17). In NZB/W mice,
a murine model of SLE (18), inflamed kidneys may provide
additional survival niches for long-lived plasma cells (19).
Like their short-lived counterparts, long-lived plasma
cells are generated in secondary lymphoid organs (14) such
as the LNs and spleen, which apparently provide only few
survival niches for the cells (20). Most plasma cells either
die within these organs (21) or leave the organs in search of
survival niches elsewhere (13). After immunization, 
 
 
 
5%
of antigen-specific plasma cells persist in the spleen com-
pared with 95% in the BM (14, 22, 23).
In the present study, we showed that long-lived plasma
cells, including autoreactive plasma cells, constitute a major
population in the spleen of NZB/W mice. Since these cells
are resistant to cyclophosphamide, selective elimination of
autospecific long-lived plasma cells is a provocative chal-
lenge to researchers aiming to develop new autoimmune
disease treatment strategies.
 
Materials and Methods
 
Mice and Immunizations.
 
Female NZB/W mice were bred at
the animal facility of the Deutsches Rheumaforschungszentrum
Berlin under defined, pathogen-free conditions. Mice aged 20–
24 wk were used in the experiments. Selected mice were immu-
nized with OVA as described previously (14). D42/NZB/W
females (24) were bred in the animal facility of the Hebrew Uni-
versity Medical School. To assess the effect of cyclophosphamide,
we fed the mice bromodeoxyuridine (BrdU) for 14–21 d before
treating them with 35 mg/kg body weight (BW) cyclophospha-
mide i.p. at various time intervals. Single-cell suspensions of
spleen were analyzed by FACS
 
®
 
 and ELISPOT 7 d after the ini-
tial cyclophosphamide treatment.
 
FACS
 
®
 
 Analysis of BrdU Incorporation.
 
These mice received
drinking water containing BrdU (1 mg/ml; Sigma-Aldrich)/1%
glucose, which was carefully protected from light and changed
every 3 d. Single-cell suspensions of spleen were filtered through
a 70-
 
 
 
m cell strainer (BD Falcon) and washed twice with PBS/
0.5% BSA. The cells were first incubated with anti-CD16/CD32
(clone 2.4G2; BD Biosciences) and rat Ig (Biotrend) for 15 min
on ice and then with anti-CD138–PE (clone 281–2; BD Bio-
sciences) for 15 min. They were then washed and subsequently
fixed and stained for BrdU (BrdU-Flow-Kit; BD Biosciences) ac-
cording to the manufacturer’s protocol. Anti-BrdU–FITC (clone
3D4; BD Biosciences), anti-D42 idiotype rabbit IgG (provided
by D. Eilat, Hadassah Medical School, Jerusalem, Israel), and
Cy5-conjugated OVA (Sigma-Aldrich) were used for intracellu-
lar staining. Anti–Dig-Cy5 (Roche), SA-Cy5 (Amersham Bio-
sciences), and goat anti–rabbit IgG-Cy5 were used as secondary
reagents. Cytometric analysis was performed using a FACSCali-
bur cytometer (BD Biosciences) with CellQuest software (BD
Biosciences). Debris and RBCs were excluded by electronic gat-
Figure 1. Kinetics and incorporation of BrdU in
the splenic plasma cell compartment of NZB/W
mice. (A) Total number of ASCs in spleen, as deter-
mined by ELISPOT, at the times indicated. Some
groups were fed BrdU continuously (B). Splenic
CD138-positive cells consist of dividing and nondi-
viding cells. NZB/W mice with confirmed SLE
were continuously fed BrdU for 2 wk. CD138-
positive cells were then FACS® sorted and stained
for intracellular immunoglobulin (red) and BrdU
(green/yellow); original magnification, 160   (left)
and 80   (right). Plasma cells negative for BrdU
had not undergone DNA synthesis or replication
during the period of BrdU treatment. Dividing
plasmablasts and plasma cells recently derived from
proliferating precursors are BrdU positive. 
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ing. Absolute cell numbers were calculated based on population
frequencies and total cell numbers per organ. To evaluate an-
nexin V binding to plasma cells and plasmablasts, single-cell sus-
pensions of spleen were incubated with annexin V (Annexin V
staining kit; BD Biosciences) according to the manufacturer’s
protocol. The samples were then counterstained with CD138-PE
and propidium iodide and run on the FACSCalibur with
CellQuest software.
 
Quantification of Antibody-secreting Cells by ELISPOT.
 
Single-
cell suspensions of spleen were washed and resuspended in RPMI
1640 medium supplemented with 10% FCS (Invitrogen), penicil-
lin, streptomycin, and glutamine (complete medium). We used a
modified standard ELISPOT technique as described previously
(19). Briefly, ELISPOT plates were coated with methyl-BSA (1
 
 
 
g/ml; Serva electrophoresis, 2 h at 37
 
 
 
C) and then washed with
PBS/0.01% Tween 20 (Merck); they were subsequently coated
with calf thymus DNA (1 
 
 
 
g/ml; Serva Electrophoresis) and in-
cubated overnight at 4
 
 
 
C in PBS. The cells were then pipetted
onto the plates and analyzed for DNA-specific antibody-secreting
cells (ASCs).
 
Fluorescence Microscopy.
 
CD138-positive spleen cells were
sorted by FACS
 
®
 
 (Moflo-Sorter), placed on slides (2 
 
 
 
 10 
 
5
 
 cells/
slide), and cytospun. The cells were then fixed with ice-cold ace-
tone and counterstained for kappa light chain (clone 187.1; BD
Biosciences). Cells for anti-BrdU staining analysis were first
treated with 2 N HCl for 1 h and then washed to yield a pH of 7
and incubated for 1 h with 600 
 
 
 
g DNase I (Sigma-Aldrich) in 1
ml buffer (1 ml in 150 mM NaCl, 5 mM MgCl
 
2
 
, 10 
 
 
 
M HCl).
BrdU incorporation was visualized by staining the cells with anti-
BrdU–Alexa 488 antibody (clone PRB-1; Molecular Probes) be-
fore examining them by confocal laser scanning microscopy (DM
IRE2; Leica).
 
Results
 
Proliferation of ASCs in the Spleens of NZB/W Mice.
 
In
NZB 
 
 
 
 NZW F1 mice (NZB/W) at least 4–5 mo of age
with full-blown murine SLE (18), the total number of
ASCs is normal in the BM but severely increased in the
spleen (19), the organ where B cells are induced to form
plasma cells. In the spleens of healthy mice, ASCs do not
make up 
 
 
 
0.1% of the total number of mononuclear cells
even after immunization (14). The vast majority of these
ASCs are short-lived plasmablasts; only a few are long-lived
(20). The frequency of splenic plasma cells increases about
threefold (to 1–2%) in NZB/W mice between the ages of
1–5 mo and before the development of proteinuria. The
numbers of ASCs in NZB/W mice 5 mo of age are 
 
 
 
20-
fold higher than in healthy mice (19). Thereafter, the fre-
quencies and absolute numbers of splenic plasma cells re-
main stable (Fig. 1 A).
Here, plasma cell turnover in the spleens of NZB/W
mice was determined based on BrdU incorporation. Mice
4–5 mo of age were continuously fed BrdU for variable pe-
riods of up to 12 wk. Consequently, cells that replicated
their DNA during this period were labeled and could
be identified using antibodies recognizing DNA-contain-
ing BrdU (25). Potentially, long-term feeding with BrdU
could have mutagenic effects that might influence the for-
mation or persistence of plasma cells. To exclude this possi-
bility, the absolute numbers and frequencies of splenic
ASCs were determined by both ELISPOT and FACS
 
®
 
(Fig. 1 A and Fig. 2 C). There were no detectable differ-
ences between mice fed BrdU for up to 12 wk and age-
matched controls that did not receive the drug. Particularly
spleen size and absolute numbers of ASCs (Fig. 1 A) were
Figure 2. The splenic plasma cell compartment consists of continu-
ously dividing cells and a stable population of nondividing cells. NZB/W
mice with confirmed SLE were continuously fed BrdU. Splenic plasma
cells (CD138-positive) were enumerated by flow cytometry at various
sampling times. (A) FACS® analysis. Plasma cells were detected by
CD138 staining. Debris was excluded from the analysis by electronic gat-
ing. (B) Kinetics of BrdU incorporation in splenic plasma cells based on
FACS® analysis. Mean values for five mice are shown. The results are
those from one run of two performed. (C) The absolute number of
BrdU-negative, nondividing plasma cells was calculated based on their
frequency and the absolute number of splenic cells. Each dot resembles an
individual mouse. 
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not altered by feeding with BrdU. This suggests that in
these experiments BrdU did not significantly modulate the
induction or persistence of plasma cells.
CD138 (syndecan-1) was used for cytometric identifica-
tion of ASCs (21). More than 95% of CD138
 
 
 
 cells in tis-
sue sections or isolated from spleens by FACS
 
®
 
 expressed
intracellular kappa light chains and exhibited either a lym-
phoblastoid or plasma cell morphology (Fig. 1 B) identify-
ing them as plasmablasts or plasma cells. Many of these cells
remained BrdU negative even after 2–9 wk of continuous
BrdU feeding (Fig. 1 B). This indicates that they had not
undergone DNA synthesis or replication during the treat-
ment period.
 
Short-lived Plasmablasts and Long-lived Plasma Cells in the
NZB/W Spleen.
 
The kinetics of BrdU incorporation into
CD138
 
 
 
 antibody-secreting spleen cells was analyzed by
cytometry (Fig. 2 A). About 60% of CD138
 
 
 
 cells became
BrdU positive within 10 d of BrdU feeding (Fig. 2 B). The
other 40% were not labeled and remained BrdU negative
for the entire period of BrdU feeding, i.e., 12 wk. The to-
tal number of BrdU-negative CD138
 
 
 
 plasma cells did not
change during these 3 mo (Fig. 2 C), suggesting that these
cells are long-lived, nondividing plasma cells.
To exclude the possibility that dividing plasmablasts
might not have been labeled due to blockage of BrdU up-
take and/or incorporation into the DNA of those cells, we
also assessed the efficiency of BrdU incorporation in OVA-
specific plasmablasts and plasma cells that develop in the
immune response to this antigen. BrdU feeding was started
at the time point of immunization to allow labeling of
all plasmablasts regardless whether they are precursors of
short-lived or long-lived plasma cells. In accordance with
our earlier observations, the majority of OVA-specific
plasma cells were located in the BM several weeks (here, 6,
9 and 12 wk) after immunization. All OVA-specific plas-
mablasts and plasma cells in the spleen and BM of NZB/W
mice became and remained BrdU positive during 6–12 wk
of continuous BrdU feeding (Fig. 3). Thus, all newly
formed plasma cells took up BrdU during BrdU feeding.
As determined by ELISOT, the frequencies and numbers
of OVA-specific ASCs in mice fed with BrdU did not dif-
fer from those in control animals. In conclusion, the BrdU-
negative plasma cells and their precursors observed in the
spleens of NZB/W mice fed BrdU did not synthesize
DNA during the period of BrdU feeding (Fig. 2 A).
Despite the presence of large numbers of BrdU-positive,
dividing plasmablasts, the numbers of nondividing, BrdU-
negative plasma cells in the spleens of NZB/W mice did
not significantly increase over time, i.e., they were not sig-
nificantly replaced by newly generated plasma cells. There-
fore, we investigated the possibility that the newly gen-
erated plasmablasts might be short-lived themselves or
that they might differentiate into short-lived plasma cells.
MHCII is expressed on early ASCs but is absent on mature
plasma cells (14). Expression of this marker correlates well
with the expansion phase of the ASC population and could
therefore be used as a surrogate marker to distinguish
proliferating plasmablasts from noncycling plasma cells
(14). This is in accordance with the observation that all
long-lived BrdU-negative CD138-positive plasma cells ex-
pressed little MHCII (Fig. 4). Roughly half of the BrdU-
positive, CD138-positive cells expressed high levels of this
molecule; the other half expressed low levels. This finding
Figure 3. BrdU efficiently labels all newly formed plasma cells. Mice
were continuously fed BrdU and immunized and boosted with OVA 3–4
wk later. After fixation, intracellular staining with fluorochrome-labeled
OVA was performed to identify plasma cells secreting OVA-specific anti-
bodies. OVA-specific plasma cells in the spleen (top) and BM (bottom)
were enumerated 6, 9, and 12 wk after boost immunization. During the
whole period between boost immunization and analysis, mice were con-
tinuously fed with BrdU. Representative data, as shown, are obtained 6
wk after boost immunization when BrdU incorporation into OVA-specific
plasma cells was already complete (n   5). Similar results were obtained 9
and 12 wk after immunization.
Figure 4. Increased binding of early MHCII-positive plasma cells to
annexin V. Fixed cells from mice fed with BrdU for 2 wk were stained
for CD138, BrdU, and MHCII. Result is shown on cells gated for
CD138 expression (top). Frequencies of BrdU-positive, MHCII-negative
CD138-positive cells were 32.5   9% (n   5). Living early plasma cells
were distinguished from mature plasma cells by MHCII expression (below)
and were stained for annexin V. Dead cells and debris were excluded
according to propidium iodide staining and forward scatter profile. Histo-
gram plots were additionally gated on CD138-negative, CD138-positive/
MHCII-negative or CD138-positive/MHCII-positive cells. 
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suggests that during the period of BrdU feeding, a fraction
of the dividing plasmablasts differentiated into more ma-
ture plasma cells, expressing little MHCII. Compared
with CD138-negative splenic cells and CD138-positive/
MHCII-low plasma cells, binding of annexin V, a marker
for early apoptosis, was increased on CD138-positive/
MHCII-positive early plasma cells (Fig. 4).
Collectively, these results show that the splenic ASC
population in NZB/W mice with an established murine
SLE consists of roughly 60% dividing plasmablasts, at least a
fraction of which are short-lived cells that die before differ-
entiating into mature MHCII-low plasma cells. The re-
maining 40% of splenic ASC are nondividing, long-lived
MHCII-low plasma cells. They constitute a stable popula-
tion of 
 
 
 
10
 
5
 
 cells, which is over 10 times higher than the
total ASC population in the spleens of nonautoimmune
CB20 and BALB/c mice (19).
Unlike their short-lived counterparts, long-lived plasma
cells are refractory to cyclophosphamide. Long-lived lym-
phocytes are considered to be resistant to immunosuppres-
sive treatment (26). Our finding that roughly half of the
splenic ASCs in NZB/W mice are long-lived plasma cells
made us wonder whether these cells are responsible for
treatment-resistant antibody titers and autoantibody pro-
duction. To clarify these points, we analyzed the plasma
cell compartment of NZB/W mice treated experimentally
with cyclophosphamide, a drug also used to treat severe
SLE in humans (Fig. 5). Three doses of 35 mg/kg BW,
higher than the amount normally used for high dose hu-
man therapy, deleted short-lived BrdU-positive plasma-
blasts nearly completely while affecting long-lived BrdU-
negative plasma cells to a much lesser extent. Higher doses
(up to 140 mg/kg) depleted larger numbers of long-lived
plasma cells, but a fraction of these cells survived even un-
der these conditions. These results show that cyclophos-
phamide therapy prevents ongoing immune activation and
formation of short-lived plasmablasts but does not delete
long-lived plasma cells efficiently.
 
Short-lived and Long-lived Plasma Cell Populations Contain
Anti-DNA Cells.
 
To determine whether ASCs were
present in the short- or long-lived plasma cell compart-
ments, we took advantage of the preferential deletion of
short-lived cells by cyclophosphamide and used ELISPOT
to determine whether anti-DNA ASCs were among the
remaining cells. Although BrdU-positive short-lived plas-
mablasts were eliminated by high doses (three to four times
35 mg/kg) of cyclophosphamide (Fig. 5), an average of
 
 
 
20% of the total IgG/IgM anti-DNA ASC survived this
extreme treatment (Table I). Although these findings sug-
gest that a fraction of the autoreactive cells is contained
within the therapy-resistant long-lived plasma cell com-
partment, it could not formally be excluded that the re-
maining BrdU-positive cells are those secreting anti-DNA
Figure 5. Long-lived plasma
cells in NZB/W mice are resistant
to conventional immunotherapy.
Mice were fed BrdU for 2–4 wk
and received the total cyclophos-
phamide dose indicated (divided
over 3 d) 1 wk before sampling.
BrdU-positive (short-lived) and
-negative (long-lived) plasma cells
were identified by FACS®. Rep-
resentative data for 25 untreated
and 12 treated mice are shown.
 
Table I.
 
 Number of Splenic ASCs in Cyclophosphamide-treated NZB/W Mice 
 
Samples CY
Number of IgG
 
  
 
ASC/spleen
Number of IgM
 
 
 
 
ASC/spleen
Number of DNA-IgG
 
 
 
 
ASC/spleen
Number of DNA-IgM
 
 
 
 
ASC/spleen
 
mg/kg
 
14  
 
  
 
35 414 
 
  
 
76 18,675 
 
  
 
3,297 5 
 
  
 
0 130 
 
  
 
23
24  
 
  
 
35 4,680 
 
  
 
1,464 24,150 
 
  
 
687 94 
 
  
 
19 496 
 
  
 
120
33  
 
  
 
35 616 
 
  
 
140 20,538 
 
  
 
6,865 49 
 
  
 
6 344 
 
  
 
40
43  
 
  
 
35 2,093 
 
  
 
217 23,625 
 
  
 
11,137 58 
 
  
 
6 351 
 
  
 
38
53  
 
  
 
35 1,485 
 
  
 
63 9,788 
 
  
 
997 72 
 
  
 
12 432 
 
  
 
114
6 — 1,3050 
 
  
 
3,307 45,000 
 
  
 
3,182 155 
 
  
 
23 783 
 
  
 
90
7 — 68,625 
 
  
 
14,319 69,750 
 
  
 
6,364 1,141 
 
  
 
108 2,653 
 
  
 
259
8 — 81,000 
 
  
 
6,364 73,125 
 
  
 
4,773 1,782 
 
  
 
187 2,025 
 
  
 
147
9 — 10,575 
 
  
 
7,319 20,250 
 
  
 
0 1,215 
 
  
 
343 1,823 
 
  
 
192
Animals 4–5 mo of age with confirmed SLE received the cyclophosphamide (CY) dose indicated. The spleens of the mice were analyzed by ELISPOT
7 days after initiation of treatment. 
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antibodies. To further investigate this point, we analyzed
the plasma cell compartment in knock-in NZB/W mice
transgenic for the anti-DNA D42 heavy chain. With this
autoimmunogenic background, the D42 heavy chain trans-
gene combines with the appropriate light chain to produce
high affinity anti-DNA IgM and IgG autoantibodies (24).
With this model, plasma cells producing DNA-binding an-
tibodies can also be monitored by staining intracellular im-
munoglobulins with an V
 
H
 
11-specific rabbit anti-idiotypic
antibody. On the NZB/W background, 
 
 90% of cells de-
tected with that reagent bind to DNA with high affinity
(24). Based on BrdU incorporation, the frequencies of
short-lived plasmablasts and long-lived plasma cells in the
spleens of D42H transgenic NZB/W mice were very simi-
lar to those observed in nontransgenic NZB/W mice (Fig.
6). About 20% of the D42 transgene–expressing plasma
cells were contained within the BrdU-negative long-lived
plasma cell compartment after 12 wk of BrdU feeding. This
is a direct indication that autoreactive cells can enter the
compartment of long-lived plasma cells. These results show
that a considerable proportion of the persistent autoanti-
body production in lupus can be mediated by long-lived
plasma cells.
Discussion
Autoantibodies can contribute significantly to the immu-
nopathology of autoimmune diseases. There is impressive
evidence for this, e.g., the spontaneous development of lu-
pus-like disease in MRL/lpr mice. In this mouse strain, dis-
ease-related mortality is reduced by  50% by rendering the
mice deficient in the production of serum antibodies (27).
During flares of autoimmune diseases like SLE, serum titers
of pathogenic autoantibodies, e.g., those directed against
dsDNA, nucleosomes, or SmD1, increase dramatically (3,
28, 29). In patients with sustained disease activity, e.g., in
those who are consequently included in experimental ther-
apeutic approaches like autologous stem cell transplanta-
tion, these antibodies can persist despite aggressive cyclo-
phosphamide therapy (30, 31). Furthermore, antibodies to
several other autoantigens observed in SLE and other au-
toimmune disorders are known to remain stable after im-
munosuppressive therapy (7, 8, 32). Traditionally, the per-
sistent secretion of autoantibodies and of serum antibodies
in general is considered to be the result of the continuous
activation of specific B lymphocytes and their differentia-
tion into short-lived plasma cells (33). However, it recently
became clear that long-lived plasma cells residing in the
BM can maintain the humoral memory provided by se-
creted serum antibodies (11, 12, 13, 14). Since these plasma
cells do not divide, they are neither sensitive to irradiation
nor to cell division inhibitors. The murine model of SLE
studied here shows that such long-lived plasma cells can be
part of an autoimmune response; hence, they provide a
provocative target for novel immunosuppressive therapies.
An earlier study suggested that the production of au-
toantibodies can be mediated by two independent mecha-
nisms which have not been characterized in detail (34).
Here, we showed that murine SLE autoantibodies are se-
creted by short-lived plasmablasts and long-lived plasma
cells. Equal numbers of both types of ASCs coexist in the
spleens of NZB/W mice with manifest disease. High doses
of cyclophosphamide (three to four times 35 mg/kg BW)
completely suppressed the formation of short-lived plas-
mablasts but were less effective in suppressing the long-
lived plasma cells. The numerical reduction in long-lived
plasma cells may well be an indirect effect, since the over-
all size of the spleen is reduced at these concentrations.
This could indicate the destruction of survival niches for
long-lived plasma cells by the treatment. We and other in-
vestigators have shown that survival of long-lived plasma
cells is dependent on a supportive environment, i.e., spe-
cific survival niches, which can be found in BM, inflamed
tissue, and to a limited extent in the normal spleen (13, 16,
20, 35). It is remarkable that the spleens of NZB/W mice
provide such niches for  10 times more long-lived plasma
cells than those of normal mice. A complete molecular
definition of plasma cell survival niches is still lacking (15,
16). The present work makes it clear that a significant in-
crease in the number of such niches occurs in NZB/W
mice before the age of 5 mo. Our finding that long-lived
plasma cells in NZB/W spleens secrete mostly IgM (Table
I and unpublished data), an isotype dominating the early
autoantibody response, supports the idea that the cells in
question had been generated in an initial flare of the dis-
ease. Between the ages of 5 and 8 mo, the number of
long-lived plasma cells remained constant. Annexin V
staining showed that a fraction of the splenic plasma-
blasts were apoptotic (Fig. 4), suggesting that these cells
are short-lived. The stable numbers of splenic long-lived
plasma cells enumerated during the observation period in-
dicate that these short-lived plasmablasts do not contribute
significantly to the long-lived splenic plasma cell compart-
ment. Whether some of these cells leave the spleen and
differentiate into long-lived plasma cells in other organs
remains unclear.
It should be noted that the number of plasma cells in the
BM of diseased NZB/W mice was not significantly higher
Figure 6. Autoreactive cells can enter the long-lived plasma cell com-
partment. D42 knock-in mice with an NZB/W genetic background
were fed BrdU for 12 wk. The spleens of the mice were then analyzed by
FACS® for the presence of BrdU-negative plasma cells (left). D42 transgene-
bearing plasma cells were detected by CD138 and intracellular staining
with an VH11-specific anti-idiotypic antibody. On the NZB/W back-
ground,  90% of cells detected with that reagent bind to DNA with high
affinity (24) (middle). Gating on D42-positive/CD138-positive plasma
cells as shown allowed the identification of BrdU-positive and BrdU-
negative plasma cells expressing the D42 transgene (right). Results are
representative data from four mice.Hoyer et al. 1583
than in normal mice (19). Less than 4   103 DNA-specific
plasma cells were detected in the BM of 7-mo-old NZB/
W mice (unpublished data). This is low compared with
the number of NZB/W plasma cells generated in an anti-
genic response against a potent immunogen. 50 d after
secondary immunization, the BM of NZB/W mice im-
munized with OVA contains  2    105 OVA-specific
plasma cells. Roughly 2   104 OVA-specific plasma cells
could be detected in the spleens of these mice at that time
(unpublished data).
The spleen normally is not a major site of persistent anti-
body secretion (23). The dramatic pathologic increase in
plasma cells in the NZB/W spleen might be due to expres-
sion of the inflammatory chemokine IP10 (CXCL10) in
that organ (36). IP10 attracts early plasmablasts that express
CXCR3 and is presumably a major physiological factor in
the relocation of plasmablasts to inflamed tissue (18, 35). It
remains unclear why and how plasmablasts generated in T
cell–dependent immune responses to the antigen OVA
leave the spleen and home in on the BM since they also are
attracted by ligands for CXCR3 (36). One could speculate
that plasmablasts of T cell–dependent responses against
nonself antigens such as OVA and of autoimmune re-
sponses are generated in distinct areas of the spleen, e.g., in
germinal centers versus extrafollicular areas. For MRL/lpr
mice, it has been demonstrated conclusively that splenic
autoreactive B cells can proliferate, undergo somatic hy-
permutation and differentiate into plasmablasts at the T
zone red pulp border (37). In such a scenario, local inflam-
matory chemokine production might retain site-specific
autoreactive plasmablasts. On the other hand, these sites do
not appear to support the long-term survival of the plasma-
blasts in light of their short half-life. This scenario must be
different in the early stages of the disease, when large num-
bers of survival niches for plasma cells apparently are gen-
erated in the spleen, giving autoreactive plasmablasts a
chance to form a prominent population of long-lived
splenic plasma cells. Based on the kinetics of BrdU incor-
poration, their half-life is estimated to be in the range of at
least 6–9 mo. This is roughly equivalent to the half-life of
long-lived plasma cells formed in a protective immune
response to lymphocytic choriomeningitis virus (12). It
should be noted that these estimates represent minimum
values. Long-lived plasma cells in humans could well sur-
vive for a half-life of several years or decades as long as they
are maintained in a functional survival niche. The present
results suggest that reversion of the inflammatory patho-
physiology of the spleen in lupus-prone NZB/W mice
may be one way to target autoreactive long-lived plasma
cells residing primarily in the spleen as opposed to protec-
tive long-lived plasma cells residing in the BM. In any case,
the elimination of autospecific, long-lived plasma cells is a
challenge to researchers developing novel immunosuppres-
sive treatment strategies.
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